Thursday, January 27, 2022
processing....
Schizophrenia
'Dark Genome' May Hold the Key to Treatment of Mental Illnesses
Skill Checkup: A 55-Year-Old Man With Schizophrenia and New-Onset Involuntary Movements
Childhood-Onset Schizophrenia
Researchers Find a New, Simpler Way to Assess Cognitive Function
Link Between Brain Cell Development and Schizophrenia Uncovered
Is There a Link Between Psychiatric Disorders and Increased COVID-19 Mortality?
0.25 CME / CE / ABIM MOC Credits
Siblings of People With Bipolar Disorder Have Higher Cancer Risk
COMMENTARY
The Gospel on Antipsychotic Drugs According to CATIE
Jeffrey A Lieberman, MD
DisclosuresOctober 01, 2009
Citation: Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223. Epub 2005 Sep 19. Available at: www.medscape.com/medline/abstract/16172203 Accessed September 29, 2009.
Medscape Psychiatry © 2009 Medscape, LLC
Cite this: Jeffrey A Lieberman. The Gospel on Antipsychotic Drugs According to CATIE - Medscape - Oct 01, 2009.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Jeffrey A Lieberman, MD
Professor and Chairman of Psychiatry, Columbia College of Physicians and Surgeons, New York, NY
Disclosure: Jeffrey A. Lieberman, MD, has disclosed the following relevant financial relationships:
Receives grants for clinical research from: Allon; Forest Laboratories; Intracellular Therapies; Merck & Co., Inc.; and Pfizer Inc.
Served as an advisor or consultant for: Bioline; Intracellular Therapies; Eli Lilly and Company
Other: Repligen (patent)